Insulet Corporation (PODD) : During the past 4 weeks, traders have been relatively bearish on Insulet Corporation (PODD), hence the stock is down -4.54% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.96% relative to the S&P 500. The 4-week change in the price of the stock is -5.06% and the stock has fallen -6.81% in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.41% and the 50-Day Moving Average is 1.02%.The 200 Day SMA reached 19.61%
Insulet Corporation (NASDAQ:PODD): After opening at $40.42, the stock dipped to an intraday low of $39.92 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $41.07 and the buying power remained strong till the end. The stock closed at $40.94 for the day, a gain of 3.57% for the day session. The total traded volume was 797,877. The stocks close on the previous trading day was $40.94.
Insulet Corporation (PODD) : The most positive equity analysts on Insulet Corporation (PODD) expects the shares to touch $52, whereas, the least positive believes that the stock will trade at $38 in the short term. The company is covered by 13 Wall Street Brokerage Firms. The average price target for shares are $43.25 with an expected fluctuation of $4.69 from the mean.
Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.